Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 10/2005

01-10-2005 | Original Research Article

Pilot Study of On-Demand Therapy with Pantoprazole 20mg for Long-Term Treatment in Patients with Mild Gastro-Oesophageal Reflux Disease

Authors: Dr Theo Scholten, Uwe Pustlauk, Peter Sander, Martina Bohuschke, Gudrun Gatz

Published in: Clinical Drug Investigation | Issue 10/2005

Login to get access

Abstract

Background: Few clinical studies have demonstrated the efficacy of proton pump inhibitors (PPIs) as on-demand therapy for the long-term management of patients with mild gastro-oesophageal reflux disease (GORD). On-demand therapy with pantoprazole 20mg may offer an effective strategy for the management of mild GORD.
Methods: Patients with mild GORD grade 0 or 1 and heartburn of at least moderate intensity at the start of the study were treated with pantoprazole 20mg once daily for 28 days (n = 254). Patients with no heartburn during the final 3 days of the acute treatment phase entered the long-term treatment phase and took pantoprazole 20mg on demand for 6 months. Antacids were provided as rescue medication during this phase. The primary endpoint was the percentage of patients unwilling to continue the study because of insufficient control of symptoms. In addition, the intensities and the relapse rates for heartburn, acid eructation and epigastric pain were determined.
Results: At the end of the acute treatment phase, 234 of 254 patients (92.1 %) were free from heartburn and entered the long-term treatment phase (intention-to-treat [ITT]). The time until study discontinuation because of inadequate control of heartburn during the on-demand treatment phase ranged from 9 to 147 days. In the ITT population, only 2.8% of patients were unwilling to continue the study because of insufficient heartburn control. Relapse rates were 4.3% for heartburn, 2.3% for acid eructation and 1.0% for epigastric pain. After 6 months of on-demand treatment, 82% of patients stated that improvements in their symptoms were maintained. For symptom control during the on-demand phase, patients took one tablet of pantoprazole 20mg every 2.3 days. Additionally, patients took one magaldrate tablet every 2.4 days.
Conclusion: Results of this pilot study show that on-demand therapy with pantoprazole 20mg appears to be an effective treatment strategy for the long-term treatment of mild GORD. Treatment acceptance by patients was high.
Literature
1.
Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51Suppl. 1: 24–9PubMedCrossRef
2.
Wienbeck M, Barnert J. Epidemiology of reflux disease andreflux esophagitis. Scand J Gastroenterol 1989; 156: 7–13CrossRef
3.
Tytgat GN, Nio CY, Schotborgh RH. Reflux esophagitis. Scand J Gastroenterol Suppl 1990; 175: 1–12PubMedCrossRef
4.
Schepp W. Proton pump inhibitory therapy: then and now. Yale J Biol Med 1996 Mar–Apr; 69(2): 175–186PubMed
5.
Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000 May; 6(9 Suppl.): S491–505PubMed
6.
Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9Suppl. 1: 15–25PubMed
7.
Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997 Sep; 11Suppl. B: 66B–73BPubMed
8.
Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998 Feb; 10(2): 119–24PubMedCrossRef
9.
Vigneri S, Termini R, Leandro G, et al. Comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995 Oct 26; 333(17): 1106–10PubMedCrossRef
10.
Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994 Aug 1; 121(3): 161–7PubMed
11.
Bardhan KD. Pantoprazole: a new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today 1999; 35(10): 773–808PubMed
12.
Lee JM, O’Morain CA. Trends in the management of gastro-oesophageal reflux disease. Postgrad Med J 1998 Mar; 74(869): 145–50PubMedCrossRef
13.
Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients with gastrooesophageal reflux disease. Gut 1992 Aug; 33(8): 1016–9PubMedCrossRef
14.
Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-de-mand’ therapy for 6 months. Aliment Pharmacol Ther 2001 Mar; 15(3): 347–54PubMedCrossRef
15.
Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40mg and 20mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002 Aug; 14(8): 857–63PubMedCrossRef
16.
Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999 Jul; 13(7): 907–14PubMedCrossRef
17.
Wahlqvist P, Junghard O, Higgins A, et al. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 2002; 20(4): 267–77PubMedCrossRef
18.
Scholten T, Dekkers CPM, Schütze K, et al. On-demand therapy with pantoprazole 20mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion 2005 Aug 19; 72(2): 76–85PubMedCrossRef
19.
Kaspari S, Kupcinskas L, Heinze H, et al. On-demand therapy with pantoprazole 20mg as effective long-term management of patients suffering from mild GERD. Eur J Gastroenterol Hepatol 2005; 17: 935–41PubMedCrossRef
20.
Janssen W, Meier E, Gatz G, et al. Pantoprazole 20mg on-demand and continuous are comparably effective for long-term management of patients with mild GERD. Current Therapeutic Res 2005; 66(4): 345–63CrossRef
21.
Savary M, Miller G. Das Oesophagus-Lehrbuch und endoskopischer Atlas. Soluthurn: Gassmann, 1977
22.
Siewert JR, Ottenjann R, Heilmann K, et al. Therapy and prevention of reflux esophagitis. Results of a multicenter study with cimetidine. I. Epidemiology and results of acute therapy. Z Gastroenterol 1986; 24: 381–95PubMed
23.
Armstrong D, Pare P, Pericak D. Canadian Pantoprazole GERD Study Group. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001 Oct; 96(10): 2849–57PubMed
24.
Lehmann FS, Beglinger C. Role of pantoprazole in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother 2005 Jan; 6(1): 93–104PubMedCrossRef
25.
Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003 Sep 15; 18(6): 587–94PubMedCrossRef
26.
Richter JE, Fraga P, Mack M, et al. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther 2004 Sep 1; 20(5): 567–75PubMedCrossRef
27.
Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer protonpump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001 Jul; 23(7): 998–1017PubMedCrossRef
28.
Kaspari S, Biedermann A, Mey J. Comparison of pantoprazole 20mg to ranitidine 150mg b.i.d. in the treatment of mild gastroesophageal reflux disease. Digestion 2001; 63(3): 163–70PubMedCrossRef
29.
van Zyl JH, de K Grundling H, van Rensburg CJ, et al. Efficacy and tolerability of 20mg pantoprazole versus 300mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study. Eur J Gastroenterol Hepatol 2000 Feb; 12(2): 197–202PubMedCrossRef
30.
Ramirez-Barba EJ, Dibildox M, Bernai F, et al. Low-dose pantoprazole (20mg) is effective for treatment of mild reflux oesophagitis. Clin Drug Invest 1999; 18(6): 445–51CrossRef
31.
Bytzer P, Blum A, De Herdt D, et al. Six-month trial of on-demand rabeprazole 10mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004 Jul 15; 20(2): 181–8PubMedCrossRef
32.
Venables TL, Newland RD, Patel AC, et al. Maintenance treatment for gastro-oesophageal reflux disease: a placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997 Jul; 32(7): 627–32PubMedCrossRef
33.
Escourrou J, Deprez P, Saggioro A, et al. Maintenance therapy with pantoprazole 20mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999 Nov; 13(11): 1481–91PubMedCrossRef
34.
Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10mg or 20mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut 1995 Apr; 36(4): 492–8PubMedCrossRef
35.
Lauritsen K, Jaup B, Carling L, et al. Comparable efficacy of pantoprazole and omeprazole to prevent relapse in patients with GERD. Gut 2000; 47(Suppl III): 39 [A60]
36.
Johnsson F, Moum B, Vilien M, et al. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002 Jun; 37(6): 642–7PubMedCrossRef
Metadata
Title
Pilot Study of On-Demand Therapy with Pantoprazole 20mg for Long-Term Treatment in Patients with Mild Gastro-Oesophageal Reflux Disease
Authors
Dr Theo Scholten
Uwe Pustlauk
Peter Sander
Martina Bohuschke
Gudrun Gatz
Publication date
01-10-2005
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 10/2005
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200525100-00002

Other articles of this Issue 10/2005

Clinical Drug Investigation 10/2005 Go to the issue

Original Research Article

Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon α-2a

Case Report

Fatal Anaphylactic Reaction to Intravenous Cephalexin

Original Research Article

Fluoroquinolone Therapy for Uncomplicated Skin and Skin Structure Infections

Original Research Article

In Vivo Comparative Pharmacokinetics and Pharmacodynamics of Moxifloxacin and Levofloxacin in Human Neutrophils

Short Communication

Simulated Fluctuations in Plasma Drug Concentrations for Patients Receiving Oxcarbazepine or Carbamazepine Extended-Release Capsules

Original Research Article

Evaluation of the Efficacy and Tolerability of Acarbose in Patients with Diabetes Mellitus